Draft synthesis: Weight-reducing agents for obstructive sleep… — disposition

§3Disposition and amendments

§3.1Disposition table

Table 1. Every submission with its disposition. Each row links to the submission in full.

§3.2Summary by disposition

Table 2. Counts by disposition, with the meaning of each.

§3.3Resulting amendments

1. The document is unreadable without specialist training — arising from DRAFT-SLEEP-APNOEA/007. Every document now opens with a plain-language summary of not more than 150 words, placed above the technical abstract and carrying the same certainty language, so that the two cannot diverge.
2. A sponsor trial meeting the eligibility criteria was excluded — arising from DRAFT-SLEEP-APNOEA/012. The trial is added to the included set, the estimate and the certainty rating have been recomputed, and the screening record now states why the trial was missed, which was a database indexing gap rather than a screening judgement. The submission is identified…
3. Subgroup findings are reported that were not registered in the protocol — arising from DRAFT-SLEEP-APNOEA/013. Every subgroup analysis is now labelled as pre-specified or post hoc against the registered protocol, post hoc analyses are reported in a separate subsection without a certainty rating, and the protocol version against which the labelling was made is stated.
4. A surrogate outcome is used as the anchor without validation evidence — arising from DRAFT-SLEEP-APNOEA/008. Where the anchor is a surrogate, the synthesis now states the evidence for the surrogate relationship, rates it separately, and downgrades the anchor rating for indirectness accordingly rather than carrying the surrogate as though it were the outcome of…
5. The search strategy as published cannot be re-run — arising from DRAFT-SLEEP-APNOEA/005. The full line-by-line strategy for each database is now published with the interface, the run date and the yield at each line, and the total retrieved is reconciled against the screening flow.
6. Results at materially different follow-up durations are pooled — arising from DRAFT-SLEEP-APNOEA/001. Estimates are now reported by duration band, with the number of contributing trials and participants in each band stated, and no estimate is pooled across bands.
7. Regulatory assessment documents were not searched — arising from DRAFT-SLEEP-APNOEA/014. Published regulatory assessment documents are now searched as a named source, are reported as a distinct evidence class in the included-studies table, and contribute to the assessment while being excluded from pooled estimates where risk of bias could not be…
8. Overlapping primary studies across included reviews are counted more than once — arising from DRAFT-SLEEP-APNOEA/015. Overlap between included reviews is now assessed at primary-study level and reported in a citation matrix, and participant totals are reported for the union of primary studies rather than as a sum across reviews.
9. Absence of evidence is presented in a form a reader will take as negative evidence — arising from DRAFT-SLEEP-APNOEA/010. A standing formulation has been adopted and is applied wherever an evidence gap is recorded, distinguishing an outcome assessed and not demonstrated from an outcome not assessed. The formulation is identical at every occurrence so that it can be recognised at…
10. Studies using different outcome definitions are pooled into one estimate — arising from DRAFT-SLEEP-APNOEA/009. Studies are now pooled only within an outcome definition, each definition is reported with its own estimate and certainty rating, and the summary of findings states which definition each row concerns.
11. The review does not say when it will be updated or what would trigger an update — arising from DRAFT-SLEEP-APNOEA/003. Every synthesis now records a scheduled review date and a stated update trigger, being the reporting of a trial that would materially change the contributing evidence, and the registered trials capable of triggering an update are listed by name.
12. A single-trial result is presented in the visual form of a pooled estimate — arising from DRAFT-SLEEP-APNOEA/004. Outcomes contributed by a single trial are now reported without a pooled diamond, labelled as unreplicated, and downgraded for imprecision or inconsistency according to the framework rather than presented as a synthesis.
13. Intention-to-treat and efficacy-estimand results are combined without distinction — arising from DRAFT-SLEEP-APNOEA/016. The treatment-policy estimand is used throughout as the primary analysis, the efficacy estimand is reported as a secondary analysis where available, and the estimand used is stated in every row of the summary of findings.
14. The choice of effect measure is not justified and changes the appearance of the result — arising from DRAFT-SLEEP-APNOEA/011. Every outcome now reports the relative effect and, where an assumed baseline risk can be stated and sourced, the corresponding absolute effect, with the baseline risk and its source given in the same row.

References cited on this page

References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.

1. International Organization for Standardization. ISO/IEC 17025:2017 General Requirements for the Competence of Testing and Calibration Laboratories. ISO/IEC Standard 2017;3rd edition. identifier not held by the Institute

Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.